Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis
NCT05363891Phase 2Completed
- Sponsor
- XBiotech Inc.
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of XB2001 in rheumatoid arthritis (RA) (3 arms), sponsored by XBiotech Inc. Primary endpoint: ACR 20 Response Rate at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
XB2001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05363891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363891.